Novartis Pharma Services AG

2 trials 1 recruiting Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

13 Countries active

6 Unique IMPs

100% Results reported

Phase III

Phase IV

Phase III: 1 Phase IV: 1

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Chronic graft versus host disease in liver 1 Acute graft versus host disease 1 B-cell lymphoma 1 Chronic graft versus host disease in intestine 1 Acute graft versus host disease in skin 1 Acute graft versus host disease in liver 1 Chronic graft versus host disease 1 Chronic graft versus host disease in skin 1 Acute graft versus host disease in intestine 1 B-cell type acute leukaemia 1

Top IMPs

AUTOLOGOUS T-CELLS ENCODING A CHIMERIC ANTIGEN RECEPTOR TARGETING HUMAN B CELL MATURATION ANTIGEN 1 PANOBINOSTAT 1 RAPCABTAGENE AUTOLEUCEL 1 RUXOLITINIB 1 SIREMADLIN 1

All trials

2 total

CAR T-cell therapy long term follow-up Recruiting

2023-508128-37-00 Phase III 12 countries AUTOLOGOUS T-CELLS ENCODING A CHIMERIC ANTIGEN RECEPTOR TARGETING HUMAN B CELL M…
An open label, multi-center, Phase IV rollover protocol to evaluate long term safety data Ended

2024-515283-31-00 Phase IV 4 countries PANOBINOSTAT; RUXOLITINIB; SIREMADLIN

Showing 1–2 of 2 trials

← All sponsors A–Z